Dr Hendrik-Tobias Arkenau is the founding Medical Director of Sarah Cannon Research Institute UK, and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the Hospital Corporation of America International Cancer Service Line.Dr Arkenau has vast experience in Early Oncology Clinical Drug Development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. As part of SCRI’s collaboration with University College London (UCL), Dr Arkenau is appointed as a Professorial Research Associate on UCLs faculty and he holds an Honorary Consultant post with UCL Hospitals.